Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular and coronary disease, will present at three upcoming conferences: the William Blair Life Sciences Conference at the Intercontinental New York Barclay, the Robert W. Baird Health Care Conference at the New York Palace, and the Sixth Annual JMP Securities Health Care Conference at the St. Regis New York. President and Chief Executive Officer David L. Martin and Chief Financial Officer Laurence L. Betterley will provide an overview of the company and its growth opportunities.


William Blair Life Sciences Conference
Wednesday, Sept. 7; 10:50 a.m. ET
Intercontinental New York Barclay
New York

Robert W. Baird Health Care Conference
[Q&A format, no webcast]
Wednesday, Sept. 7; 1:15 p.m. ET
The New York Palace
New York

Sixth Annual JMP Securities Health Care Conference
Tuesday, Sept. 27; 11 a.m. ET
St. Regis New York
New York


To listen to a live webcast of the presentations at the William Blair Life Sciences Conference and Sixth Annual JMP Securities Health Care Conference, go to the investor information section of the company’s Web site,, and click on the respective webcast icon.
If you have any difficulty accessing the webcasts, please contact

Mick Forgey: (612) 455-1789;

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Stealth 360°™, Diamondback 360® and Predator 360® PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007 and for the Stealth 360° in March 2011. To date, more than 50,000 PAD procedures have been performed using CSI’s PAD systems in leading institutions across the United States.

CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.

For more information, visit the company’s website at

Copyright Business Wire 2010